Inactivation of glycogen synthase kinase-3␤ (GSK3␤) by S 9 phosphorylation is implicated in mechanisms of neuronal survival. Phosphorylation of a distinct site, Y 216 , on GSK3␤ is necessary for its activity; however, whether this site can be regulated in cells is unknown. Therefore we examined the regulation of Y 216 phosphorylation on GSK3␤ in models of neurodegeneration. Nerve growth factor withdrawal from differentiated PC12 cells and staurosporine treatment of SH-SY5Y cells led to increased phosphorylation at Y 216 , GSK3␤ activity, and cell death. Lithium and insulin, agents that lead to inhibition of GSK3␤ and adenoviralmediated transduction of dominant negative GSK3␤ constructs, prevented cell death by the proapoptotic stimuli. Inhibitors induced S 9 phosphorylation and inactivation of GSK3␤ but did not affect Y 216 phosphorylation, suggesting that S 9 phosphorylation is sufficient to override GSK3␤ activation by Y 216 phosphorylation. Under the conditions examined, increased Y 216 phosphorylation on GSK3␤ was not an autophosphorylation response. In resting cells, Y 216 phosphorylation was restricted to GSK3␤ present at focal adhesion sites. However, after staurosporine, a dramatic alteration in the immunolocalization pattern was observed, and Y 216 -phosphorylated GSK3␤ selectively increased within the nucleus. In rats, Y 216 phosphorylation was increased in degenerating cortical neurons induced by ischemia. Taken together, these results suggest that Y 216 phosphorylation of GSK3␤ represents an important mechanism by which cellular insults can lead to neuronal death.
A berrant cell death within the adult central nervous system is a key mechanism thought to underlie the pathology of several neurodegenerative diseases (1, 2) . Survival growth factors protect neurons from a variety of proapoptotic stimuli, and one of the protective mechanisms has been attributed to the activation of the phosphoinositide-3 kinase signal transduction pathway (3) . A downstream effector of this signaling pathway is Akt, a kinase that phosphorylates the serine͞threonine kinase GSK3␤ on S 9 to render it inactive (4, 5), a proposed mechanism by which neurons become resistant to apoptotic stimuli (6) (7) (8) .
A second regulatory site (Y 216 ), which lies within the activation loop between subdomains VII and VIII of the catalytic domain, has been identified on GSK3␤ and whose phosphorylation is necessary for functional activity (9) . Dephosphorylation with a protein tyrosine phosphatase or mutation of Y 216 on GSK3␤ results in a dramatic decrease in activity (9) . It is unclear whether Y 216 is a site for GSK3␤ autophosphorylation or whether a separate tyrosine kinase phosphorylates this site to activate GSK3␤ (10) .
In addition to its role in apoptosis, GSK3␤ hyperphosphorylates the microtubule-associated protein , a mechanism implicated in paired helical filament formation in Alzheimer's disease (11, 12) . Despite progress in defining growth factor-dependent pathways that regulate S 9 phosphorylation (13), little is known regarding the regulation of GSK3␤ activity by Y 216 phosphorylation in neurons. As a first step, we have determined whether the Y 216 residue on GSK3␤ is subject to regulation in models of neurodegeneration. Our results indicate that Y 216 phosphorylation on GSK3␤ is robustly increased in response to apoptotic stimuli in neuronal cells and in brain. Y 216 -phosphorylated GSK3␤ is localized to focal adhesion points that are disrupted after an apoptotic stimulus and selectively increase within the nucleus. The increased Y 216 phosphorylation does not occur via an autophosphorylation mechanism, implying that in neurons, proapoptotic stimuli lead to activation of an undetermined tyrosine kinase pathway leading to the phosphorylation of GSK3␤ on Y 216 and its activation.
Materials and Methods
Materials. Rat pheochromocytoma (PC12) cells and human neuroblastoma SH-SY5Y cells were obtained from American Type Culture Collection (Rockville, MD). Antibodies and sources: polyclonal phospho-specific Y 216 and S 9 GSK3␤ antibodies (QCB-Biosource International, Camarillo, CA); monoclonal GSK3␤ antibody (Transduction Laboratories, Lexington, KY); monoclonal vinculin antibody, nerve growth factor (NGF) (2.5S), and polyclonal anti-NGF (Sigma); Texas red-labeled phalloidin, Oregon green 488-labeled goat anti-rabbit, and Texas red-labeled goat anti-mouse secondary antibodies (Molecular Probes). Recombinant human (rh) GSK3␤ was provided by Philip Cohen, University of Dundee, Dundee, Scotland, U.K. The elongation initiation factor 2b peptide substrate was provided by Peninsula Laboratories. ␥ 33 P-ATP (specific activity 10 Ci͞l) was from Amersham Pharmacia Biotech.
Apoptosis Induction. PC12 cells were differentiated for 9-12 days in RPMI containing 1% FBS and 50 ng͞ml NGF. Apoptosis was induced by washing cells with NGF-free medium and was accelerated by the addition of anti-NGF antibodies (1:400). In SH-SY5Y cells, apoptosis was induced by using staurosporine (0.1-0.3 M). Quantification of apoptosis was done by measuring fragmented DNA by using a Cell Death Detection kit as specified by the manufacturer (Boehringer-Mannheim, catalogue no. 1774425).
Immunoprecipitation and Kinase Assay. For immunoprecipitation, 10 g of cell lysate prepared in ice-cold lysis buffer (10 mM This paper was submitted directly (Track II) to the PNAS office.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Tris⅐HCl, pH 7.5͞50 mM NaCl͞30 M Na 4 P 2 O 7 ͞1% Triton-X͞ 0.2 mM PMSF͞7.5 g/ml leupeptin͞7 g/ml each pepstatin A, aprotinin, and E-64͞10 g/ml benzamidine͞2 mM Na 3 VO 4 ͞2.5 mM NaF) was incubated with 5 l antibody for 1 h at 4°C followed by overnight incubation with P-AT P (0.2 Ci)͞10 mM Mg(Ac) 2 ͞10 mM Mops, pH7.0͞0.2 mM EDTA in a total volume of 50 l. Reaction was initiated with ATP (30 min at 30°C) and was stopped by spotting 40 l onto P81 phosphocellulose paper filters. Filters were washed with 75 mM phosphoric acid, rinsed with acetone, and quantitated by scintillation counting. Western blotting and detection were performed as previously described by using antibodies at 1:1,000 dilution (14) .
Construction of Vectors for Homologous Recombination in Bacteria.
pAdeasy-1, pAdTrack-CMV plasmids and Escherichia coli BJ5183 were obtained from Bert Vogelstein, The Johns Hopkins Oncology Center, Baltimore, MD. GSK3␤ cDNA was obtained from the American Type Culture Collection image clone collection. A hemagglutinin (HA) epitope tag was introduced by PCR, and the construct was cloned into pAd-CMVtrack by using BglII and EcoRV sites. The K85R and Y216F mutations were generated by point mutagenesis of the GSK3␤ clone by using the QuickChange Kit from Stratagene. Constructs were verified by sequencing and restriction digest.
Recombinant adenoviruses of wild-type (wt) and mutant GSK3␤ constructs were produced by using the AdEasy System, Quantum Biotechnologies (Montreal, Canada). Cell number was estimated by counting, and the appropriate multiplicity of infection was delivered. Infection was performed in 2% serum (2 h), then normal serum was added for 12 h.
Cerebral Ischemia Model. Long-Evans rats (180-220 g) were given food and water ad libitum and housed in an American Association for the Accreditation of Laboratory Animal Care accredited facility. Animals were injected s.c. with lithium chloride or saline, once daily for 16 days (1.5 meq͞kg day 1-4; 2.3 meq͞kg day 5-11; 3 meq͞kg day 12-16), as previously described (15) . Twenty-four hours after the last injection, rats were subjected to unilateral cerebral ischemia by 90 min of filament-induced middle cerebral artery occlusion (MCAO), as described (15) . The infarcted area (mm 3 ) for each slice was determined by an image analyzer. For immunohistochemistry, tissue was processed as described previously (14) .
Confocal Microscopy and Immunohistochemistry. SH-SY5Y cells grown on coverslips were fixed in 4% paraformaldehyde in PBS at reverse transcription (RT) for 15 min. Cells were permeabilized in 0.2% Triton X-100 in PBS and blocked in 1% BSA in PBS for 15 min. Primary and secondary antibody incubations [rabbit anti-Y 216 (1:500) or mouse anti-vinculin (1:500) in blocking reagent, goat anti-rabbit conjugated with Oregon Green 488 (1:1,000)], or goat anti-mouse conjugated with Texas red (1:1,000) or Texas red phalloidin (1:100) were done for 30 min at RT. Each step was followed by a 15-min wash with PBS. Coverslips were mounted in Vectashield (Vector Laboratories) and photographed on an Olympus Fluoview 300 (Olympus, New Hyde Park, NY) confocal microscope by using a ϫ100 objective.
Results
Apoptotic cell death was measured after NGF deprivation in PC12 cells by using an assay that detects fragmented DNA, a phenomenon associated with endonuclease cleavage of DNA into 180 base pairs during apoptosis. Apoptosis was observed within 3 h after NGF withdrawal and remained elevated for 24 h (Fig. 1A) . At 3 h after NGF withdrawal, Hoescht staining confirmed that 20-25% of cells exhibited apoptotic morphology. To test whether GSK3␤ activity was altered in the apoptosis model, we performed a GSK3␤ kinase assay on proteins immunoprecipitated from cell lysates with a monoclonal GSK3␤ antibody. NGF withdrawal (3 h) resulted in a 6-fold increase in GSK3␤ activity that was blocked by lithium (10 mM) or insulin (1 M), treatments known to result in inhibition of GSK3␤ activity (Fig. 1B) .
In vitro studies indicate that phosphorylation of Y 216 residue on GSK3␤ is essential for its activity (9) . Therefore, we determined whether Y 216 phosphorylation on GSK3␤ was altered after NGF deprivation by using phospho Y 216 -specific antibodies. The phosphorylation specificity of the Y 216 antibody was confirmed by using active rhGSK3␤ in the presence or absence of alkaline phosphatase (Fig. 1C) . Furthermore, the phospho-Y 216 -specific antibody did not detect HA-immunoprecipitated GSK3␤ from 293 transfected cells wherein the Y 216 residue was mutated to phenylalanine (Y216F-GSK3␤-HA, not shown). Within 1 h after NGF withdrawal, a rapid and persistent increase in GSK3␤ Y 216 phosphorylation was observed, suggesting that Y 216 phosphorylation is an early event during apoptosis (Fig.  1D) . We also evaluated the phosphorylation of S 9 , a site on GSK3␤ that, when phosphorylated, renders GSK3␤ inactive. Under basal conditions, neither S 9 nor Y 216 phosphorylation was detected, and the low activity was confirmed by using GSK3␤ immunokinase assays. NGF withdrawal did not affect S 9 phosphorylation on GSK3␤.
In addition to direct inhibition of GSK3␤ by lithium (17), insulin and lithium activate Akt and result in the subsequent inactivation of GSK3␤ (ref. 16 and Fig. 1B) . Thus, we evaluated the effects on Y 216 and S 9 phosphorylation of GSK3␤ by these agents. Lithium pretreatment (10 mM, 16 h) or insulin (1 M, 3 h) addition to PC12 cells undergoing apoptosis resulted in S 9 phosphorylation (Fig. 1E) , consistent with the notion that these agents are activating kinases that phosphorylate GSK3␤ on S may not be caused by autophosphorylation. To explore this possibility further, we tested whether GSK3␤ that completely lacks intrinsic kinase activity, i.e., K85R-GSK3␤-HA could be phosphorylated at Y 216 in response to NGF withdrawal. By using a recombinant adenovirus strategy, we achieved Ϸ90% transduction of wt GSK3␤-HA and K85R-GSK3␤-HA constructs (visualization of green fluorescent protein incorporated into the constructs). K85R-GSK3␤-HA immunoprecipitated from cells was phosphorylated on Y 216 similar to wt GSK3␤-HA after NGF withdrawal (Fig. 1F) . Because inactivation of GSK3␤ did not prevent NGF withdrawal-induced Y 216 phosphorylation, it is likely that Y 216 is not an autophosphorylation site.
Lithium (16 h) and insulin (3 h) also blocked NGF withdrawalinduced apoptosis (IC 50 ϭ 1.3 mM and 117 nM, respectively) . In initial studies, the effects of lithium (10 mM) and insulin (1 M) were examined on cell viability [by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay]. The doses of lithium and insulin used had no effect on MTT formation, indicating the lack of overt toxic effects. On treatment, cells were relatively intact and similar to NGFdifferentiated PC12 cells in morphology, with extensive neurites visible ( Fig. 2A) . Because lithium is not a specific inhibitor of GSK3␤, its neuroprotective effects could be mediated via other Akt-mediated survival mechanisms; therefore, we examined the effect of the K85R-GSK3␤ mutant on apoptosis. Compared with mock-infected PC12 cells, infection of the K85R-GSK3␤ mutant decreased NGF withdrawal-induced apoptosis by Ϸ60% (Fig.  2B) . Immunokinase assays confirmed that GSK3␤ activity was reduced by 85% when compared with mock-infected cells, indicating that the K85R-GSK3␤ mutant was acting as a dominant negative protein. The cells appeared healthy with intact neurites after infection of K85R-GSK3␤ in NGF-deprived PC12 cells (Fig. 2B Right) . Thus inactivation of GSK3␤ is critical in preventing NGF withdrawal-induced apoptosis in PC12 cells.
To evaluate whether the increase in Y 216 phosphorylation was unique to the NGF deprivation paradigm or occurred in other models of apoptosis, we examined the responses in staurosporine-treated SH-SY5Y cells. Addition of staurosporine (100 nM) resulted in a time-dependent increase in apoptosis and in Y 216 phosphorylation of GSK3␤ (Fig. 3A) . Both lithium (IC 50 ϭ 13 mM) and adenoviral-mediated transduction of K85R-GSK3␤ blocked apoptosis induced by staurosporine, confirming the importance of GSK3␤'s role in neuronal apoptosis. When visualized under microscopy, Ͼ95% of the K85R-GSK3␤-infected cells (multiplicity of infection ϭ 1) showed resistance to staurosporine-induced apoptosis (see Fig. 3B ).
To determine whether the Y 216 phosphorylation of GSK3␤ was a result of autophosphorylation in the staurosporineinduced apoptosis model, we virally transduced HA-tagged wt GSK3␤ and K85R-GSK3␤ (multiplicity of infection ϭ 100) in SH-SY5Y cells and then treated them with staurosporine. Immunoprecipitation with the anti-HA antibody and blotting with the phospho-specific Y 216 antibody revealed that both wt GSK3␤-HA and K85R-GSK3␤-HA were phosphorylated at the Y 216 site in response to staurosporine treatment (Fig. 3C) . Because K85R-GSK3␤-HA lacks intrinsic kinase activity but was Y 216 phosphorylated on staurosporine treatment, the phosphorylation could not have occurred by autophosphorylation.
Confocal imaging was used to define the subcellular distribution of Y 216 -phosphorylated GSK3␤. In resting cells, phospho-Y 216 immunofluorescence was observed at focal adhesion sites as defined by colocalization with the terminal regions of actin filaments (Fig. 4A ) and the focal adhesion protein vinculin (Fig.  4D) . Minimal Y 216 -phosphorylated GSK3␤ was observed in the nucleus (Fig. 4A Center) . In contrast, cells treated with staurosporine showed a change in the pattern of Y 216 -phosphorylated GSK3␤ from focal adhesion sites to the nuclear compartment apparent as early as 5 min (Fig. 4B) and at 30 min after addition of 300 nM staurosporine (Fig. 4C) . Thus the morphological changes that occur during apoptosis coincide with a differential localization of the Y 216 -phosphorylated GSK3␤. Additional experiments are necessary to determine whether this represents a translocation or simply a change in the levels of GSK3␤ phosphorylation within the nucleus.
We used focal ischemia (MCAO model) in rats to determine whether the changes observed in cell culture models were indicative of an in vivo response. Focal ischemia results in a loss of cortical neurons and represents an acute model of neurodegeneration. Western blot analysis revealed that as early as 3 and 6 h after MCAO, an increase in Y 216 phosphorylation is observed in the ipsilateral but not contralateral cortex (Fig. 5A) . Immunostaining on tissue sections showed prominent Y 216 phosphorylation in the cortex ipsilateral to the ischemic insult (Fig. 5B) . Preadsorption of the primary antibody with excess peptide (ϫ100) completely blocked the immunostaining (not shown). Phosphorylated Y 216 immunostaining was localized in the cytoplasm and dendrites of the cortical pyramidal neurons; however, several neurons also exhibited nuclear immunostaining at 6 h after MCAO. Silver staining of the brains at 6 h after ischemia confirmed the presence of degenerating neurons in the cortex. 
Discussion
This study provides evidence for the regulation and localization of Y 216 phosphorylation on GSK3␤ in neuronal apoptosis and after ischemia in rats. The major findings are that Y 216 phosphorylation of GSK3␤ occurs as part of an apoptotic response in neurons and that this site is not autophosphorylated under the conditions studied. The phosphorylation of Y 216 was transient, preceded the induction of apoptosis, and increased in the nucleus during apoptosis. These results suggest that Y 216 phosphorylation of GSK3␤ represents an important alternate mechanism by which cellular insults such as growth factor deprivation and staurosporine treatment can lead to neuronal death.
Our finding that GSK3␤ inhibition attenuates neuronal apoptosis is consistent with recent reports (6-8) ; however, the downstream mechanism is poorly understood. GSK3␤ phosphorylates cytosolic proteins including ␤-catenin and mitochondrial pyruvate dehydrogenase (18, 19) , as well as nuclear proteins such as c-Jun, NFAT-c, and elongation initiation factor 2b (20, 21) , yet linking the phosphorylation of any one protein to an apoptotic pathway remains controversial. GSK3␤ plays a key role in phosphorylating and promoting paired helical filament formation (11) , the appearance of which is associated with early neuritic changes in Alzheimer's disease. Recently, active GSK3␤ localized to pretangle neurons (22) . GSK3␤-induced phosphorylation could cause neuritic dysfunction and trigger apoptosis, thereby linking two key pathologies found in Alzheimer's disease brains.
We show that Y 216 is not subject to autophosphorylation because an inactive GSK3␤ mutant became Y 216 phosphorylated in response to apoptotic stimuli. This suggests that the Y 216 site can be phosphorylated by an upstream yet-to-be-deciphered signal transduction pathway. Recently, insulin and increased cytosolic calcium were shown to result in phosphorylation through an elevation of GSK3␤ kinase activity (23, 24) . The accompanying phosphorylation on GSK3␤ was detected by general antiphospho-tyrosine antibodies, thus whether this represented direct phosphorylation at the Y 216 site or an indirect inhibition of the pathway leading to S 9 phosphorylation is unclear (23) . Our study provides initial evidence for the direct phosphorylation of GSK3␤ at the Y 216 site by a protein kinase other than GSK3␤, resulting in increased activity during apoptosis.
Under normal conditions, Y
216
-phosphorylated GSK3␤ was restricted to focal adhesion sites, a localization consistent with a role for GSK3␤ in neurite elongation and retraction (25, 26) . Several tyrosine kinases form a complex at focal adhesion sites including FAK and Fyn kinase (27, 28) . Fyn coimmunoprecipitates with GSK3␤ in SH-SY5Y cells on insulin addition (23) . In neurons, ␤-amyloid increases Fyn kinase and GSK3␤ activity (29) and inhibition of either kinase is neuroprotective (29, 30) . Although it is tempting to speculate that the fyn kinase pathway results in the Y 216 phosphorylation of GSK3␤ in neurons, which then translocates to the nucleus to participate in a proapoptotic cascade, further work is necessary to determine the validity of this hypothesis.
We demonstrate that after cerebral ischemia, Y 216 phosphorylation of GSK3␤ is increased in neurons vulnerable to apoptosis, and lithium, a nonselective GSK3␤ inhibitor, was neuroprotective. Thus GSK3␤ could play a role in neuronal disorders in which apoptosis has been suggested as a common molecular mechanism. If this is true, GSK3␤ inhibitors would be therapeutically useful in attenuating the course of both acute and chronic neurodegenerative diseases.
